BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 11147584)

  • 1. In microdissected ductal carcinoma in situ, HER-2/neu amplification, but not p53 mutation, is associated with high nuclear grade and comedo histology.
    Ho GH; Calvano JE; Bisogna M; Borgen PI; Rosen PP; Tan LK; Van Zee KJ
    Cancer; 2000 Dec; 89(11):2153-60. PubMed ID: 11147584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast. Immunohistochemical and sequencing data.
    O'Malley FP; Vnencak-Jones CL; Dupont WD; Parl F; Manning S; Page DL
    Lab Invest; 1994 Jul; 71(1):67-72. PubMed ID: 8041120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 missense mutations in microdissected high-grade ductal carcinoma in situ of the breast.
    Done SJ; Eskandarian S; Bull S; Redston M; Andrulis IL
    J Natl Cancer Inst; 2001 May; 93(9):700-4. PubMed ID: 11333292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.
    Xu R; Perle MA; Inghirami G; Chan W; Delgado Y; Feiner H
    Mod Pathol; 2002 Feb; 15(2):116-24. PubMed ID: 11850540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 mutations in mammary ductal carcinoma in situ but not in epithelial hyperplasias.
    Done SJ; Arneson NC; Ozçelik H; Redston M; Andrulis IL
    Cancer Res; 1998 Feb; 58(4):785-9. PubMed ID: 9485035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic variables in invasive breast cancer: contribution of comedo versus noncomedo in situ component.
    Brower ST; Ahmed S; Tartter PI; Bleiweiss I; Amberson JB
    Ann Surg Oncol; 1995 Sep; 2(5):440-4. PubMed ID: 7496840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer.
    Bull SB; Ozcelik H; Pinnaduwage D; Blackstein ME; Sutherland DA; Pritchard KI; Tzontcheva AT; Sidlofsky S; Hanna WM; Qizilbash AH; Tweeddale ME; Fine S; McCready DR; Andrulis IL
    J Clin Oncol; 2004 Jan; 22(1):86-96. PubMed ID: 14701769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Her-2/neu gene amplification in ductal carcinoma in situ of the breast.
    Hoque A; Sneige N; Sahin AA; Menter DG; Bacus JW; Hortobagyi GN; Lippman SM
    Cancer Epidemiol Biomarkers Prev; 2002 Jun; 11(6):587-90. PubMed ID: 12050101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential amplification and overexpression of HER-2/neu, p53, MIB1, and estrogen receptor/progesterone receptor among medullary carcinoma, atypical medullary carcinoma, and high-grade invasive ductal carcinoma of breast.
    Xu R; Feiner H; Li P; Yee H; Inghirami G; Delgado Y; Perle MA
    Arch Pathol Lab Med; 2003 Nov; 127(11):1458-64. PubMed ID: 14567723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlations among p53, Her-2/neu, and ras overexpression and aneuploidy by multiparameter flow cytometry in human breast cancer: evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinomas.
    Smith CA; Pollice AA; Gu LP; Brown KA; Singh SG; Janocko LE; Johnson R; Julian T; Hyams D; Wolmark N; Sweeney L; Silverman JF; Shackney SE
    Clin Cancer Res; 2000 Jan; 6(1):112-26. PubMed ID: 10656439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ideas in pathology. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification association between cellular proliferation and c-erbB-2 protein expression.
    Poller DN; Silverstein MJ; Galea M; Locker AP; Elston CW; Blamey RW; Ellis IO
    Mod Pathol; 1994 Feb; 7(2):257-62. PubMed ID: 7911998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular and immunohistochemical analysis of p53 mutations in scrapings and tissue from preinvasive and invasive breast cancer.
    Lisboa BW; Vogtländer S; Gilster T; Riethdorf L; Milde-Langosch K; Löning T
    Virchows Arch; 1997 Dec; 431(6):375-81. PubMed ID: 9428925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinoma. Interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression.
    Tsuda H; Akiyama F; Terasaki H; Hasegawa T; Kurosumi M; Shimadzu M; Yamamori S; Sakamoto G
    Cancer; 2001 Dec; 92(12):2965-74. PubMed ID: 11753973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of HER-2/neu expression in patients with ductal carcinoma in situ.
    Stackievicz R; Paran H; Bernheim J; Shapira M; Weisenberg N; Kaufman T; Klein E; Gutman M
    Isr Med Assoc J; 2010 May; 12(5):290-5. PubMed ID: 20929083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 mutation in breast cancer. Correlation with cell kinetics and cell of origin.
    Megha T; Ferrari F; Benvenuto A; Bellan C; Lalinga AV; Lazzi S; Bartolommei S; Cevenini G; Leoncini L; Tosi P
    J Clin Pathol; 2002 Jun; 55(6):461-6. PubMed ID: 12037031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Possible Prognostic Role of HER2/Neu in Ductal Carcinoma In Situ and Atypical Ductal Proliferative Lesions of the Breast.
    Daoud SA; Ismail WM; Abdelhamid MS; Nabil TM; Daoud SA
    Asian Pac J Cancer Prev; 2016; 17(8):3733-6. PubMed ID: 27644608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
    Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
    Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene amplifications detected by fluorescence in situ hybridization in pure intraductal breast carcinomas: relation to morphology, cell proliferation and expression of breast cancer-related genes.
    Fiche M; Avet-Loiseau H; Maugard CM; Sagan C; Heymann MF; Leblanc M; Classe JM; Fumoleau P; Dravet F; Mahé M; Dutrillaux B
    Int J Cancer; 2000 Sep; 89(5):403-10. PubMed ID: 11008201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distribution of Hsp-27 and HER-2/neu in in situ and invasive ductal breast carcinomas.
    Storm FK; Gilchrist KW; Warner TF; Mahvi DM
    Ann Surg Oncol; 1995 Jan; 2(1):43-8. PubMed ID: 7530588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.
    Ariga R; Zarif A; Korasick J; Reddy V; Siziopikou K; Gattuso P
    Breast J; 2005; 11(4):278-80. PubMed ID: 15982396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.